DMPK Gene Analysis for Myotonic Dystrophy Type I (DM1)
Myotonic dystrophy type 1 (DM1) is an autosomal dominant disorder that affects skeletal muscle, smooth muscle, eyes, heart, endocrine system, and the central nervous system. It is the most common form of adult onset muscular dystrophy. Clinically DM1 is variable in both its clinical features and time of onset. In mild DM1 the disease may appear anytime between the second and seventh decades and patients may only have cataracts and mild myotonia. The classic form of DM1 is characterized by muscle weakness and wasting, myotonia, cataracts, and cardiac conduction abnormalities and typically has its onset in the second to forth decades. The congenital form is severe and characterized by hypotonia and severe generalized weakness at birth, often with respiratory insufficiency and early death.
DM1 is caused by a heterozygous trinucleotide repeat expansion (CTG)n in the 3-prime untranslated region of the dystrophia myotonica protein kinase gene (DMPK) on chromosome 19q13. Disease severity varies with the trinucleotide repeat expansion. Normal individuals have 5 to 37 repeats while individual with classic DM1 have 100 to 1,000 repeats, and those with congenital onset can have more than 2,000 repeats. DM1 affects approximately 1 in 20,000 people. The disorder shows genetic anticipation with expansion of the repeat number to become more severe with each successive generation. Genetic testing is important for the diagnosis of DM1, determining prognosis, screening for carriers and prenatal assessment. Triplet-repeat primed PCR (TP-PCR) and Southern blotting of long-range PCR products is most common techniques use to detect DM1 expansion.
- For the diagnosis of Myotonic dystrophy type 1 (DM1)
- Prenatal genetic carrier screening in high risk patients
- Genetic carrier screening in relatives of disease affected
Normal:
5-34 CTG trinucleotide repeats
Non- pathogenic (pre-expansion alleles):
35-49 CTG trinucleotide repeats. Asymptomatic parents with CTG expansions have their children with increased risk of inheriting a larger repeat size and exhibits symptoms.
Abnormal:
>50 CTG trinucleotide repeats are associated with disease manifestations.
Normal: 5-34 CTG trinucleotide repeats
Whole blood (EDTA/lavender top tube).
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: Unacceptable
- Biomed Res Int. 2013; 2013: 391821. [PMID: 23586035]
- Neurology. 2019;93: e995-e1009. [PMID: 31395669]
- Neurology. 2000;54: 1218-21. [PMID: 10746587]
- Clin Genet. 2017;92: 355-364. [PMID: 27991661]
- Lancet Neurol. 2012;11: 891-905. [PMID: 22995693]
- Eur J Neurol. 2011;18: 207-17. [PMID: 20500522]
- Am J Med Genet A. 2009;149A(7): 1365-74. [PMID: 19514047]